Stay updated with breaking news from Complete Remission. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Approval Marks Kite's Fourth Indication in Europe for its Two Cell Therapies and First in Leukemia -- -- Overall Complete Remission of 71% and a Median Overall Survival of More Than Two Years
Primary effusion lymphoma (PEL) is a rare form of high-grade non-Hodgkin's lymphoma that usually occurs in patients with compromised immunity or human immunodeficiency virus (HIV) infection. PEL is a B-cell lymphoma that principally presents as effusions without a tumor mass. We present a case of a 56-year-old African-American male with a medical history of HIV admitted to the hospital with right lung lower lobe pneumonia and parapneumonic effusion. Thoracentesis and pleural fluid cytology led to the diagnosis of PEL. He received treatment with chemotherapy and antiretroviral therapy (AR...
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU) a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline data for DANYELZA and GM-CSF for consolidation of high-risk neuroblastoma (“HR-NB”) patients in complete re
If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia (AML) sub...